Central Nervous System Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.

Published Nov 01, 2024

Length 160 Pages

SKU # FOB19326551

Description

Central Nervous System Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Central Nervous System Treatment Market

The central nervous system treatment market size was valued at USD 81.67 billion in 2020, and the market is now projected to grow from USD 89.02 billion in 2021 to USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast period of 2021-2028.

Pandemic disrupted delivery chain of CNS therapeutics, brought about a drop in earnings of about USD 1.4 billion in 2020. Pharmaceutical corporations have shifted their research and Development expenditure and personnel closer. Over-the-counter products, like anesthesia, moreover skilled a dip in revenue boom because of decrease demand. However, the marketplace is predicted to stabilize and display surprising growth in 2021, reverting to pre-pandemic levels.

New neurological disease remedies are expected to pressure central nervous system treatment market growth, in particular in growing international locations. Corbus Pharmaceuticals Inc.'s Lenabasum, presently in Phase 3 scientific trial, is prepared to release globally through using 2023.

One of the huge traits that the market well-known shows are mergers, acquisitions, and partnerships. Predominant companies within the market concerned in innovating principal apprehensive gadget treatment capsules have entered into distribution and developmental agreements with fellow competition. For instance, in February 2020, Biogen agreed with Sangamo Therapeutics to innovate gene remedy pills for diverse neurological diseases. Such strategic steps taken by means of key groups working inside the CNS therapeutics marketplace will notably enhance the prospects of the industry.

Comprehensive Analysis of Central Nervous System Treatment Market

The market is classified into neurovascular diseases, neurodegenerative sicknesses, highbrow fitness, and infectious ailments. Neurodegenerative ailments, collectively with multiple sclerosis and Alzheimer's ailment, dominated the market due to accelerated sales and R&D investments. Mental fitness issues also are increasing due to strain, tension, and dangerous diets, with the COVID-19 pandemic inflicting an upward thrust in call for antidepressants and analgesics. The drug magnificence phase consists of immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, analgesics, and other imperative frightened remedy pills. Immunomodulators dominate the marketplace in 2020 because of consistent innovation and development of therapeutic molecules. The non-biologics phase, with Biogen's Tecfidera having the very best sales, is driven by using the growing incidence of neurological diseases, strong government guide, and favourable fitness reimbursement. The distribution channel section is split into health centre pharmacies and retail pharmacies, with online pharmacies projected to witness a lucrative CAGR because of internet penetration in emerging countries.

The North America region lead the central nervous system treatment market share by benefitting a market size of USD 38.25 billion in 2020 due to the presence of key players and higher access to CNS disorder treatment. Government agencies like the U.S. FDA are actively informing the public and healthcare professionals about treatment and regulatory guidelines for managing CNS diseases.

The market for critical worried gadget therapeutics is fragmented because of the presence of various organizations. Biogen dominates the market, with its crucial molecules generating great sales in 2020. Other players embody Johnson and Johnson Services, Pfizer, Biogen, Pfizer, Hoffman-La Roche, Novartis, Teva Pharmaceutical Industries and Otsuka Holdings.

Johnson and Johnson has obtained FDA popularity of the each day oral drug Ponvory, that is supposed for treating more than one sclerosis.

Segmentation Table

ATTRIBUTE

DETAILS

Study Period

2017-2028

Base Year

2020

Estimated Year

2021

Forecast Period

2021-2028

Historical Period

2017-2019

Unit

Value (USD billion)

Segmentation

Disease Type, Drug Class, Drug Type, Distribution Channel, and Region

By Disease Type

Neurovascular Diseases

Hemorrhagic Stroke
Ischemic Stroke
Others

Neurodegenerative Diseases

Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others

Mental Health

Epilepsy
Mood Disorders
Anxiety Disorders
Others

Infectious Diseases

Meningitis
Encephalitis
Others

Others

By Drug Class

Immunomodulatory Drugs

Interferons

Decarboxylase Inhibitors

Dopamine Agonists

Antidepressants

Analgesics

Others

By Drug Type

Biologics

Non-biologics

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America (By Disease Type, By Drug Class, By Drug Type By Distribution Channel, and By Country)

U.S. (By Drug Type)
Canada (By Drug Type)

Europe (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)

U.K. (By Drug Type)
Germany (By Drug Type)
France (By Drug Type)
Italy (By Drug Type)
Spain (By Drug Type)
Rest of Europe (By Drug Type)

Asia Pacific (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)

China (By Drug Type)
Japan (By Drug Type)
India (By Drug Type)
Australia (By Drug Type)
Southeast Asia (By Drug Type)
Rest of Asia Pacific (By Drug Type)

Latin America (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)

Brazil (By Drug Type)
Mexico (By Drug Type)
Rest of Latin America (By Drug Type)

Middle East & Africa (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)

GCC (By Drug Type)
South Africa (By Drug Type)
Rest of Middle East & Africa (By Drug Type)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities
4. Key Insights: 4.1. Key Industry Developments- Mergers, Acquisitions and Partnerships; 4.2. New Product Launches; 4.3. Pipeline Analysis; 4.4. Overview of Regulatory Scenario; 4.5. Impact of COVID-19 on the Market
5. Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028: 5.1. Key Findings / Summary; 5.2. Market Analysis, Insights and Forecast – By Drug Class; 5.2.1. Immunomodulatory Drugs; 5.2.2. Interferons; 5.2.3. Decarboxylase Inhibitors; 5.2.4. Dopamine Agonists; 5.2.5. Antidepressants; 5.2.6. Analgesics; 5.2.7. Others; 5.3. Market Analysis, Insights and Forecast – By Disease Type; 5.3.1. Neurovascular Diseases; 5.3.1.1. Hemorrhagic Stroke; 5.3.1.2. Ischemic Stroke; 5.3.1.3. Others; 5.3.2. Neurodegenerative Diseases; 5.3.2.1. Alzheimer’s Disease; 5.3.2.2. Parkinson’s Disease; 5.3.2.3. Multiple Sclerosis; 5.3.2.4. Others; 5.3.3. Mental Health; 5.3.3.1. Epilepsy; 5.3.3.2. Mood Disorders; 5.3.3.3. Anxiety Disorders; 5.3.3.4. Others; 5.3.3.5. Infectious Diseases; 5.3.3.6. Meningitis; 5.3.3.7. Encephalitis; 5.3.3.8. Others; 5.3.4. Others; 5.4. Market Analysis, Insights and Forecast – By Distribution Channel; 5.4.1. Hospital Pharmacy; 5.4.2. Retail Pharmacy; 5.4.3. Others; 5.5. Market Analysis, Insights and Forecast – By Drug Type; 5.5.1. Biologics; 5.5.2. Non-biologics; 5.6. Market Analysis, Insights and Forecast – By Region; 5.6.1. North America; 5.6.2. Europe; 5.6.3. Asia Pacific; 5.6.4. Latin America; 5.6.5. Middle East & Africa
6. North America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028: 6.1. Key Findings / Summary; 6.2. Market Analysis, Insights and Forecast – By Drug Class; 6.2.1. Immunomodulatory Drugs; 6.2.2. Interferons; 6.2.3. Decarboxylase Inhibitors; 6.2.4. Dopamine Agonists; 6.2.5. Antidepressants; 6.2.6. Analgesics; 6.2.7. Others; 6.3. Market Analysis, Insights and Forecast – By Disease Type; 6.3.1. Neurovascular Diseases; 6.3.1.1. Hemorrhagic Stroke; 6.3.1.2. Ischemic Stroke; 6.3.1.3. Others; 6.3.2. Neurodegenerative Diseases; 6.3.2.1. Alzheimer’s Disease; 6.3.2.2. Parkinson’s Disease; 6.3.2.3. Multiple Sclerosis; 6.3.2.4. Others; 6.3.3. Mental Health; 6.3.3.1. Epilepsy; 6.3.3.2. Mood Disorders; 6.3.3.3. Anxiety Disorders; 6.3.3.4. Others; 6.3.3.5. Infectious Diseases; 6.3.3.6. Meningitis; 6.3.3.7. Encephalitis; 6.3.3.8. Others; 6.3.4. Others; 6.4. Market Analysis, Insights and Forecast – By Distribution Channel; 6.4.1. Hospital Pharmacy; 6.4.2. Retail Pharmacy; 6.4.3. Others; 6.5. Market Analysis, Insights and Forecast – By Drug Type; 6.5.1. Biologics; 6.5.2. Non-biologics; 6.6. Market Analysis, Insights and Forecast – By Country; 6.6.1. U.S. (By Drug Type); 6.6.2. Canada (By Drug Type)
7. Europe Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028: 7.1. Key Findings / Summary; 7.2. Market Analysis, Insights and Forecast – By Drug Class; 7.2.1. Immunomodulatory Drugs; 7.2.2. Interferons; 7.2.3. Decarboxylase Inhibitors; 7.2.4. Dopamine Agonists; 7.2.5. Antidepressants; 7.2.6. Analgesics; 7.2.7. Others; 7.3. Market Analysis, Insights and Forecast – By Disease Type; 7.3.1. Neurovascular Diseases; 7.3.1.1. Hemorrhagic Stroke; 7.3.1.2. Ischemic Stroke; 7.3.1.3. Others; 7.3.2. Neurodegenerative Diseases; 7.3.2.1. Alzheimer’s Disease; 7.3.2.2. Parkinson’s Disease; 7.3.2.3. Multiple Sclerosis; 7.3.2.4. Others; 7.3.3. Mental Health; 7.3.3.1. Epilepsy; 7.3.3.2. Mood Disorders; 7.3.3.3. Anxiety Disorders; 7.3.3.4. Others; 7.3.3.5. Infectious Diseases; 7.3.3.6. Meningitis; 7.3.3.7. Encephalitis; 7.3.3.8. Others; 7.3.4. Others; 7.4. Market Analysis, Insights and Forecast – By Distribution Channel; 7.4.1. Hospital Pharmacy; 7.4.2. Retail Pharmacy; 7.4.3. Others; 7.5. Market Analysis, Insights and Forecast – By Drug Type; 7.5.1. Biologics; 7.5.2. Non-biologics; 7.6. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.6.1. U.K. (By Drug Type); 7.6.2. Germany (By Drug Type); 7.6.3. France (By Drug Type); 7.6.4. Spain (By Drug Type); 7.6.5. Italy (By Drug Type); 7.6.6. Scandinavia (By Drug Type); 7.6.7. Rest of Europe (By Drug Type)
8. Asia Pacific Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028: 8.1. Key Findings / Summary; 8.2. Market Analysis, Insights and Forecast – By Drug Class; 8.2.1. Immunomodulatory Drugs; 8.2.2. Interferons; 8.2.3. Decarboxylase Inhibitors; 8.2.4. Dopamine Agonists; 8.2.5. Antidepressants; 8.2.6. Analgesics; 8.2.7. Others; 8.3. Market Analysis, Insights and Forecast – By Disease Type; 8.3.1. Neurovascular Diseases; 8.3.1.1. Hemorrhagic Stroke; 8.3.1.2. Ischemic Stroke; 8.3.1.3. Others; 8.3.2. Neurodegenerative Diseases; 8.3.2.1. Alzheimer’s Disease; 8.3.2.2. Parkinson’s Disease; 8.3.2.3. Multiple Sclerosis; 8.3.2.4. Others; 8.3.3. Mental Health; 8.3.3.1. Epilepsy; 8.3.3.2. Mood Disorders; 8.3.3.3. Anxiety Disorders; 8.3.3.4. Others; 8.3.3.5. Infectious Diseases; 8.3.3.6. Meningitis; 8.3.3.7. Encephalitis; 8.3.3.8. Others; 8.3.4. Others; 8.4. Market Analysis, Insights and Forecast – By Distribution Channel; 8.4.1. Hospital Pharmacy; 8.4.2. Retail Pharmacy; 8.4.3. Others; 8.5. Market Analysis, Insights and Forecast – By Drug Type; 8.5.1. Biologics; 8.5.2. Non-biologics; 8.6. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.6.1. Japan (By Drug Type); 8.6.2. China (By Drug Type); 8.6.3. India (By Drug Type); 8.6.4. Australia (By Drug Type); 8.6.5. Southeast Asia (By Drug Type); 8.6.6. Rest of Asia Pacific (By Drug Type)
9. Latin America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028: 9.1. Key Findings / Summary; 9.2. Market Analysis, Insights and Forecast – By Drug Class; 9.2.1. Immunomodulatory Drugs; 9.2.2. Interferons; 9.2.3. Decarboxylase Inhibitors; 9.2.4. Dopamine Agonists; 9.2.5. Antidepressants; 9.2.6. Analgesics; 9.2.7. Others; 9.3. Market Analysis, Insights and Forecast – By Disease Type; 9.3.1. Neurovascular Diseases; 9.3.1.1. Hemorrhagic Stroke; 9.3.1.2. Ischemic Stroke; 9.3.1.3. Others; 9.3.2. Neurodegenerative Diseases; 9.3.2.1. Alzheimer’s Disease; 9.3.2.2. Parkinson’s Disease; 9.3.2.3. Multiple Sclerosis; 9.3.2.4. Others; 9.3.3. Mental Health; 9.3.3.1. Epilepsy; 9.3.3.2. Mood Disorders; 9.3.3.3. Anxiety Disorders; 9.3.3.4. Others; 9.3.3.5. Infectious Diseases; 9.3.3.6. Meningitis; 9.3.3.7. Encephalitis; 9.3.3.8. Others; 9.3.4. Others; 9.4. Market Analysis, Insights and Forecast – By Distribution Channel; 9.4.1. Hospital Pharmacy; 9.4.2. Retail Pharmacy; 9.4.3. Others; 9.5. Market Analysis, Insights and Forecast – By Drug Type; 9.5.1. Biologics; 9.5.2. Non-biologics; 9.6. Market Analysis, Insights and Forecast – By Country/ Sub-region; 9.6.1. Brazil (By Drug Type); 9.6.2. Mexico (By Drug Type); 9.6.3. Rest of Latin America (By Drug Type)
10. Middle East & Africa Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028: 10.1. Key Findings / Summary; 10.2. Market Analysis, Insights and Forecast – By Drug Class; 10.2.1. Immunomodulatory Drugs; 10.2.2. Interferons; 10.2.3. Decarboxylase Inhibitors; 10.2.4. Dopamine Agonists; 10.2.5. Antidepressants; 10.2.6. Analgesics; 10.2.7. Others; 10.3. Market Analysis, Insights and Forecast – By Disease Type; 10.3.1. Neurovascular Diseases; 10.3.1.1. Hemorrhagic Stroke; 10.3.1.2. Ischemic Stroke; 10.3.1.3. Others; 10.3.2. Neurodegenerative Diseases; 10.3.2.1. Alzheimer’s Disease; 10.3.2.2. Parkinson’s Disease; 10.3.2.3. Multiple Sclerosis; 10.3.2.4. Others; 10.3.3. Mental Health; 10.3.3.1. Epilepsy; 10.3.3.2. Mood Disorders; 10.3.3.3. Anxiety Disorders; 10.3.3.4. Others; 10.3.3.5. Infectious Diseases; 10.3.3.6. Meningitis; 10.3.3.7. Encephalitis; 10.3.3.8. Others; 10.3.4. Others; 10.4. Market Analysis, Insights and Forecast – By Distribution Channel; 10.4.1. Hospital Pharmacy; 10.4.2. Retail Pharmacy; 10.4.3. Others; 10.5. Market Analysis, Insights and Forecast – By Drug Type; 10.5.1. Biologics; 10.5.2. Non-biologics; 10.6. Market Analysis, Insights and Forecast – By Country/ Sub-region; 10.6.1. GCC Countries (By Drug Type); 10.6.2. South Africa (By Drug Type); 10.6.3. Rest of Middle East & Africa (By Drug Type)
11. Competitive Analysis: 11.1. Key Industry Developments; 11.2. Global Market Share Analysis (2020); 11.3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)); 11.3.1. Biogen; 11.3.1.1. Overview,; 11.3.1.2. Products,; 11.3.1.3. SWOT analysis,; 11.3.1.4. Recent developments,; 11.3.1.5. strategies,; 11.3.1.6. financials (based on availability); 11.3.2. Pfizer, Inc.; 11.3.2.1. Overview,; 11.3.2.2. Products,; 11.3.2.3. SWOT analysis,; 11.3.2.4. Recent developments,; 11.3.2.5. strategies,; 11.3.2.6. financials (based on availability); 11.3.3. F. Hoffmann-La Roche Ltd; 11.3.3.1. Overview,; 11.3.3.2. Products,; 11.3.3.3. SWOT analysis,; 11.3.3.4. Recent developments,; 11.3.3.5. strategies,; 11.3.3.6. financials (based on availability); 11.3.4. Novartis AG; 11.3.4.1. Overview,; 11.3.4.2. Products,; 11.3.4.3. SWOT analysis,; 11.3.4.4. Recent developments,; 11.3.4.5. strategies,; 11.3.4.6. financials (based on availability); 11.3.5. Johnson and Johnson Services Inc.; 11.3.5.1. Overview,; 11.3.5.2. Products,; 11.3.5.3. SWOT analysis,; 11.3.5.4. Recent developments,; 11.3.5.5. strategies,; 11.3.5.6. financials (based on availability); 11.3.6. Teva Pharmaceutical Industries Lt; 11.3.6.1. Overview,; 11.3.6.2. Products,; 11.3.6.3. SWOT analysis,; 11.3.6.4. Recent developments,; 11.3.6.5. strategies,; 11.3.6.6. financials (based on availability); 11.3.7. Sanofi; 11.3.7.1. Overview,; 11.3.7.2. Products,; 11.3.7.3. SWOT analysis,; 11.3.7.4. Recent developments,; 11.3.7.5. strategies,; 11.3.7.6. financials (based on availability); 11.3.8. Otsuka Holdings; 11.3.8.1. Overview,; 11.3.8.2. Products,; 11.3.8.3. SWOT analysis,; 11.3.8.4. Recent developments,; 11.3.8.5. strategies,; 11.3.8.6. financials (based on availability); 11.3.9. Other Prominent Players; 11.3.9.1. Overview,; 11.3.9.2. Products,; 11.3.9.3. SWOT analysis,; 11.3.9.4. Recent developments,; 11.3.9.5. strategies,; 11.3.9.6. financials (based on availability)

Pricing

Currency Rates

Single User Email from Publisher $4,850
Global Site License Email from Publisher $6,850

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now